Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer

Qu,Jingkun; Zhao,Xixi; Wang,Jizhao; Liu,Chao; Sun,Yuchen; Cai,Hui; Liu,Jianlin

doi:10.3892/ol.2018.7915

Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer

Authors:
- Jingkun Qu
- Xixi Zhao
- Jizhao Wang
- Chao Liu
- Yuchen Sun
- Hui Cai
- Jianlin Liu
View Affiliations

Affiliations: The Second Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Oncology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710004, P.R. China, Department of Vascular Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China
Published online on: January 31, 2018 https://doi.org/10.3892/ol.2018.7915
Pages: 5236-5242

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies have indicated that phospholipase A2 (PLA2) may be associated with tumorigenesis in human tissues. The present study aimed to investigate the association between plasma PLA2 activity and the breast cancer (BC) status of patients. Increased plasma PLA2 activity was detected in patients with breast cancer when compared with healthy controls. Plasma samples were obtained from patients with BC (n=169), patients with benign disease (BD; n=80) and healthy controls (n=81). PLA2 activity was assessed using a quantitative fluorescent assay with selective inhibitors. It was demonstrated that increased PLA2 and secretory PLA2 (sPLA2) activity was associated with tumor stage, particularly in patients with late‑stage disease. Additionally, smoking, alcohol consumption, body mass index (BMI) and age of patients did not have a significant effect on PLA2 activity. Analysis of receiver operating characteristic curves revealed that plasma PLA2 and sPLA2 activities were increased in BC patients compared with healthy controls. It was concluded that plasma PLA2 activity may serve as a biomarker for patients with BC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Hassan LM, Mahmoud N, Miller AB, Iraj H, Mohsen M, Majid J, Reza SM and Mojgan M: Evaluation of effect of self-examination and physical examination on breast cancer. Breast. 24:487–490. 2015. View Article : Google Scholar : PubMed/NCBI
3	Curigliano G, Spitaleri G, Dettori M, Locatelli M, Scarano E and Goldhirsch A: Vaccine immunotherapy in breast cancer treatment: Promising, but still early. Expert Rev Anticancer Ther. 7:1225–1241. 2007. View Article : Google Scholar : PubMed/NCBI
4	Li SY, Li R, Chen YL, Xiong LK, Wang HL, Rong L and Luo RC: Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients. BMC Genet. 15:672014. View Article : Google Scholar : PubMed/NCBI
5	Wang X, Huang CJ, Yu GZ, Wang JJ, Wang R, Li YM and Wu Q: Expression of group IIA phospholipase A2 is an independent predictor of favorable outcome for patients with gastric cancer. Hum Pathol. 44:2020–2027. 2013. View Article : Google Scholar : PubMed/NCBI
6	Li S, Zhao X, Wu Z, Li Y, Zhu L, Cui B, Dong X, Tian S, Hu F and Zhao Y: Polymorphisms in arachidonic acid metabolism-related genes and the risk and prognosis of colorectal cancer. Fam Cancer. 12:755–765. 2013. View Article : Google Scholar : PubMed/NCBI
7	Mirtti T, Laine VJ, Hiekkanen H, Hurme S, Rowe O, Nevalainen TJ, Kallajoki M and Alanen K: Group IIA phospholipase A as a prognostic marker in prostate cancer: Relevance to clinicopathological variables and disease-specific mortality. APMIS. 117:151–161. 2009. View Article : Google Scholar : PubMed/NCBI
8	Menschikowski M, Hagelgans A, Nacke B, Jandeck C, Mareninova OA, Asatryan L and Siegert G: Epigenetic control of group V phospholipase A2 expression in human malignant cells. Tumour Biol. 37:8097–8105. 2016. View Article : Google Scholar : PubMed/NCBI
9	Quach ND, Arnold RD and Cummings BS: Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease. Biochem Pharmacol. 90:338–348. 2014. View Article : Google Scholar : PubMed/NCBI
10	Jin Y, Yang F and Du L: Nanoassemblies containing a fluorouracil/zidovudine glyceryl prodrug with phospholipase A2-triggered drug release for cancer treatment. Colloids Surf B Biointerfaces. 112:421–428. 2013. View Article : Google Scholar : PubMed/NCBI
11	Zhu C, Sun Z, Li C, Guo R, Li L, Jin L, Wan R and Li S: Urocortin affects migration of hepatic cancer cell lines via differential regulation of cPLA2 and iPLA2. Cell Signal. 26:1125–1134. 2014. View Article : Google Scholar : PubMed/NCBI
12	Mannello F, Qin W, Zhu W, Fabbri L, Tonti GA and Sauter ER: Nipple aspirate fluids from women with breast cancer contain increased levels of group IIa secretory phospholipase A2. Breast Cancer Res Treat. 111:209–218. 2008. View Article : Google Scholar : PubMed/NCBI
13	Kondo T: Inconvenient truth: Cancer biomarker development by using proteomics. Biochim Biophys Acta. 1844:861–865. 2014. View Article : Google Scholar : PubMed/NCBI
14	Cai Q, Zhao Z, Antalis C, Yan L, Del Priore G, Hamed AH, Stehman FB, Schilder JM and Xu Y: Elevated and secreted phospholipase A₂ activities as new potential therapeutic targets in human epithelial ovarian cancer. FASEB J. 26:3306–3320. 2012. View Article : Google Scholar : PubMed/NCBI
15	Schneider AP II, Zainer CM, Kubat CK, Mullen NK and Windisch AK: The breast cancer epidemic: 10 facts. Linacre Q. 81:244–277. 2014. View Article : Google Scholar : PubMed/NCBI
16	Lanfranchi AE and Fagan P: Breast cancer and induced abortion: A comprehensive review of breast development and pathophysiology, the epidemiologic literature, and proposal for creation of databanks to elucidate all breast cancer risk factors. Issues Law Med. 29:3–133. 2014.PubMed/NCBI
17	Linos E, Spanos D, Rosner BA, Linos K, Hesketh T, Qu JD, Gao YT, Zheng W and Colditz GA: Effects of reproductive and demographic changes on breast cancer incidence in China: A modeling analysis. J Natl Cancer Inst. 100:1352–1360. 2008. View Article : Google Scholar : PubMed/NCBI
18	World Medical Association, . World medical association declaration of helsinki: Ethical principles for medical research involving human subjects. JAMA. 310:2191–2194. 2013. View Article : Google Scholar : PubMed/NCBI
19	Cai H, Chiorean EG, Chiorean MV, Rex DK, Robb BW, Hahn NM, Liu Z, Loehrer PJ, Harrison ML and Xu Y: Elevated phospholipase A2 activities in plasma samples from multiple cancers. PLoS One. 8:e570812013. View Article : Google Scholar : PubMed/NCBI
20	Sobin LH and Wittekind C: TNM classification of malignant tumors. International Union Against Cancer (UICC) (5th). 54–58. 1997.
21	Buhmeida A, Bendardaf R, Hilska M, Laine J, Collan Y, Laato M, Syrjänen K and Pyrhönen S: PLA2 (group IIA phospholipase A2) as a prognostic determinant in stage II colorectal carcinoma. Ann Oncol. 20:1230–1235. 2009. View Article : Google Scholar : PubMed/NCBI
22	Yamashita S, Yamashita J, Sakamoto K, Inada K, Nakashima Y, Murata K, Saishoji T, Nomura K and Ogawa M: Increased expression of membrane-associated phospholipase A2 shows malignant potential of human breast cancer cells. Cancer. 71:3058–3064. 1993. View Article : Google Scholar : PubMed/NCBI
23	Lovett JL, Chima MA, Wexler JK, Arslanian KJ, Friedman AB, Yousif CB and Strassmann BI: Oral contraceptives cause evolutionarily novel increases in hormone exposure: A risk factor for breast cancer. Evol Med Public Health. 2017:97–108. 2017. View Article : Google Scholar : PubMed/NCBI
24	Russo J, Moral R, Balogh GA, Mailo D and Russo IH: The protective role of pregnancy in breast cancer. Breast Cancer Res. 7:131–142. 2005. View Article : Google Scholar : PubMed/NCBI
25	Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P and Starosławska E: Breast cancer risk factors. Prz Menopauzalny. 14:196–202. 2015.PubMed/NCBI
26	Webb ML, Cady B, Michaelson JS, Bush DM, Calvillo KZ, Kopans DB and Smith BL: A failure analysis of invasive breast cancer: Most deaths from disease occur in women not regularly screened. Cancer. 120:2839–2846. 2014. View Article : Google Scholar : PubMed/NCBI
27	Howell A: The emerging breast cancer epidemic: Early diagnosis and treatment. Breast Cancer Res. 12 Suppl 4:S102010. View Article : Google Scholar : PubMed/NCBI
28	Killelea BK, Long JB, Chagpar AB, Ma X, Wang R, Ross JS and Gross CP: Evolution of breast cancer screening in the Medicare population: Clinical and economic implications. J Natl Cancer Inst. 106:pii: dju1592014. View Article : Google Scholar
29	Indovina P, Marcelli E, Pentimalli F, Tanganelli P, Tarro G and Giordano A: Mass spectrometry-based proteomics: The road to lung cancer biomarker discovery. Mass Spectrom Rev. 32:129–142. 2013. View Article : Google Scholar : PubMed/NCBI
30	Vendramini-Costa DB and Carvalho JE: Molecular link mechanisms between inflammation and cancer. Curr Pharm Des. 18:3831–3852. 2012. View Article : Google Scholar : PubMed/NCBI
31	Gurel B, Lucia MS, Thompson IM Jr, Goodman PJ, Tangen CM, Kristal AR, Parnes HL, Hoque A, Lippman SM, Sutcliffe S, et al: Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev. 23:847–856. 2014. View Article : Google Scholar : PubMed/NCBI
32	Deivendran S, Marzook KH and Radhakrishna Pillai M: The role of inflammation in cervical cancer. Adv Exp Med Biol. 816:377–399. 2014. View Article : Google Scholar : PubMed/NCBI
33	Liu Q, Tan Q, Zheng Y, Chen K, Qian C, Li N, Wang Q and Cao X: Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation. J Biol Chem. 289:11522–11535. 2014. View Article : Google Scholar : PubMed/NCBI
34	Hernández M, Martín R, García-Cubillas MD, Maeso-Hernández P and Nieto ML: Secreted PLA2 induces proliferation in astrocytoma through the EGF receptor: Another inflammation-cancer link. Neuro Oncol. 12:1014–1023. 2010. View Article : Google Scholar : PubMed/NCBI